Drug Approval | February 20, 2022
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Recall does not include any metabolic deficiency nutrition formulas
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Resolv ER may remedy leading causes of blindness in adults
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Subscribe To Our Newsletter & Stay Updated
